Jaguar Health, Inc. (JAGX): Submission of Matters to a Vote of Security Holders

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders San Francisco, CA (November 6, 2026): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced the voting results of the Company’s November 6, 2026

Event · Shareholder vote
Original reporting
Published Nov 6, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$JAGX
Neutral
high confidence
Mentioned
$JAGX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$JAGXNeutralLow
01

Why it matters

The filing confirms routine governance actions; no new capital, M&A, or product news is presented.

02

Market read

Limited relevance; primarily of interest to existing shareholders and compliance monitors.

03

What to watch

Potential future actions stemming from the approved proposals are not disclosed.

Relevance 6/10Novelty 4/10Timing: after market today

Background

The article is an unedited SEC 8‑K press release announcing the results of a special shareholders' meeting for Jaguar Health, Inc.

Company-level read

Ticker impact

$JAGXNeutralHigh confidence
Context

SEC 8‑K filing reports that shareholders approved six proposals at the November 6, 2026 special meeting.

Expected impact

no significant impact as the vote confirms existing governance actions

Evidence & confidence

The filing contains only standard corporate governance approvals without new financing, acquisitions, or material operational changes.

Market effects

none

none

none

Counterpoint

If the proposals included hidden strategic shifts, the market could react, but the filing provides no such detail.

Key entities

  • Jaguar Health, Inc.

    Biopharma company developing plant‑derived gastrointestinal drugs.

Related articles

$JAGXMed

Jaguar Health Reports Third Quarter 2026 Financials

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jaguar Health Reports Third Quarter 2026 Financials Jaguar’s rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical mile

$JAGXMedAI 8/10

Jaguar Health, Inc.: Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure in Third Rare Congenital Enteropathy Disorder

Jaguar Health (JAGX) announced that its drug crofelemer has shown benefits in treating intestinal failure in pediatric patients with GUCY2C gene mutation, reducing parenteral support needs. The company plans to file for FDA approval for MVID in mid-2027. Crofelemer has also shown promise in reducing parenteral support needs in patients with MVID and SBS-IF.

$JAGXMedAI 8/10

Jaguar Health unit treats infant with rare intestinal disorder

Jaguar Health Inc. (JAGX) announced its subsidiary Napo Pharmaceuticals is treating an infant with congenital sodium diarrhea using crofelemer, reducing parenteral support needs by 15%. The company plans to file a New Drug Application for microvillus inclusion disease in mid-2027, with trial data showing significant reductions in parenteral support for pediatric patients.